Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.57 |
| ▸ | CTSK | P43235 | 9/20 | 0.54 |
| ▸ | CTSS | P25774 | 7/20 | 0.53 |
| ▸ | CTSL | P07711 | 5/20 | 0.53 |
| ▸ | CTSB | P07858 | 3/20 | 0.53 |
| ▸ | PPARA | Q07869 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | KYNU | Q16719 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2619553 | 1.00 | SYK (0.57) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL376154 | 1.00 | SYK (0.57) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL7222412 | 0.93 | SYK (0.55) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL5970655 | 0.93 | SYK (0.55) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL30649083 | 0.91 | SYK (0.54) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL10166824 | 0.91 | SYK (0.54) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL14207360 | 0.90 | CTSK (0.63) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL13205156 | 0.90 | PPARA (0.57) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL1094804 | 0.90 | PPARA (0.57) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL1094803 | 0.90 | PPARA (0.57) | SYKCTSKCTSSCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210361772-A1 | ENZYME AND RECEPTOR MODULATION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-11-25 | — | — | US | disclosed |
| WO-2021053158-A1 | NOVEL HISTONE METHYLTRANSFERASE INHIBITORS | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2021-03-25 | — | — | WO | disclosed |
| EP-3530290-A1 | ALPHA AMINOACID ESTER-DRUG CONJUGATES HYDROLYSABLE BY CARBOXYLESTERASE | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-08-28 | — | — | EP | disclosed |
| US-20190231887-A1 | ENZYME AND RECEPTOR MODULATION | CHROMA THERAPEUTICS LTD. (GB) | 2019-08-01 | — | — | US | disclosed |
| US-20180000952-A1 | ENZYME AND RECEPTOR MODULATION | CHROMA THERAPEUTICS LIMITED (GB) | 2018-01-04 | — | — | US | disclosed |
| US-20180000952-A1 | ENZYME AND RECEPTOR MODULATION | CHROMA THERAPEUTICS LIMITED (GB) | 2018-01-04 | — | — | US | disclosed |
| EP-1964577-B1 | ALPHA AMINOACID ESTER-DRUG CONJUGATES HYDROLYSABLE BY CARBOXYLESTERASE | GLAXOSMITHKLINE IP DEV LTD (GB) | 2016-04-13 | — | — | EP | disclosed |
| US-20150126534-A1 | ENZYME AND RECEPTOR MODULATION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-05-07 | — | — | US | disclosed |
| EP-1877098-B1 | ALPHA AMINOACID ESTER-DRUG CONJUGATES HYDROLYSABLE BY CARBOXYLESTERASE | CHROMA THERAPEUTICS LTD (GB) | 2013-04-24 | — | — | EP | disclosed |
| US-8148531-B2 | Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity | CHROMA THERAPEUTICS LTD. (GB) | 2012-04-03 | — | — | US | disclosed |
| EP-1877383-A1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS INHIBITORS OF KINASE ENZYMATIC ACTIVITY | Chroma Therapeutics Limited (GB) | 2008-01-16 | — | — | EP | disclosed |
| EP-1877098-A2 | ALPHA AMINOACID ESTER-DRUG CONJUGATES HYDROLYSABLE BY CARBOXYLESTERASE | Chroma Therapeutics Limited (GB) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006117567-A2 | ALPHA AMINOACID ESTER-DRUG CONJUGATES HYDROLYSABLE BY CARBOXYLESTERASE | CHROMA THERAPEUTICS LTD (GB) | 2006-11-09 | — | — | WO | disclosed |
| WO-2006117552-A1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS INHIBITORS OF KINASE ENZYMATIC ACTIVITY | CHROMA THERAPEUTICS LTD (GB) | 2006-11-09 | — | — | WO | disclosed |
| EP-1718639-A2 | CASPASE INHIBITORS AND USES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2006-11-08 | — | — | EP | disclosed |
| US-20050233979-A1 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2005-10-20 | — | — | US | disclosed |
| WO-2005085236-A2 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-09-15 | — | — | WO | disclosed |
| US-6057314-A | ANTICOAGULANTS | BIOCHEM PHARMA INC. (CA) | 2000-05-02 | — | — | US | disclosed |
| EP-0802916-A1 | LOW MOLECULAR WEIGHT BICYCLIC THROMBIN INHIBITORS | BIOCHEM PHARMA INC (CA) | 1997-10-29 | — | — | EP | disclosed |
| WO-1996019483-A1 | LOW MOLECULAR WEIGHT BICYCLIC THROMBIN INHIBITORS | BIOCHEM PHARMA INC. (CA) | 1996-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180000952-A1 | ENZYME AND RECEPTOR MODULATION | CES1, HCAR1, DNPEP | SYK 1716/4885CTSK 723/4885CTSS 462/4885 |
| US-20210361772-A1 | ENZYME AND RECEPTOR MODULATION | CES1, HCAR1, DNPEP | SYK 1716/4885CTSK 723/4885CTSS 462/4885 |
| US-20190231887-A1 | ENZYME AND RECEPTOR MODULATION | CES1, HCAR1, DNPEP | SYK 1716/4885CTSK 723/4885CTSS 462/4885 |
| US-20150126534-A1 | ENZYME AND RECEPTOR MODULATION | CES1, HCAR1, DNPEP | SYK 1716/4885CTSK 723/4885CTSS 462/4885 |
| US-20050233979-A1 | Caspase inhibitors and uses thereof | CASP1, CASP5, CASP3 | SYK 1311/4885CTSK 67/4885CTSS 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.